Relationship between survivorship care plans and unmet information needs, quality of life, satisfaction with care, and propensity to engage with, and attend, follow-up care.
adult cancer
childhood cancer
quality of life
survivorship
survivorship care plan
unmet needs
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 12 2023
01 12 2023
Historique:
revised:
29
06
2023
received:
24
12
2022
accepted:
15
07
2023
medline:
6
11
2023
pubmed:
11
8
2023
entrez:
11
8
2023
Statut:
ppublish
Résumé
The impact of survivorship care plans (SCPs) on the proximal and distal outcomes of adult and childhood cancer survivors, and parent proxies, is unclear. This study aimed to determine the relationship between SCP receipt and these outcomes. A cross-sectional survey of adult and childhood cancer survivors (and parent proxies for survivors aged younger than 16 years) across Australia and New Zealand was conducted. Multivariate regression models were fitted to measure the impact of SCP receipt on proximal (unmet information needs and propensity to engage with, and attend, cancer-related follow-up care) and distal outcomes (quality of life and satisfaction with cancer-related follow-up care) with control for cancer history and sociodemographic factors. Of 1123 respondents, 499 were adult cancer survivors and 624 were childhood cancer survivors (including 222 parent proxies). We found that SCP receipt was predictive of greater attendance at, and awareness of, cancer-related follow-up care (adult: odds ratio [OR], 2.46; 95% CI, 1.18-5.12; OR, 2.38; 95% CI, 1.07-5.29; child/parent: OR, 2.61; 95% CI, 1.63-4.17; OR, 1.63; 95% CI, 1.06-2.50; respectively). SCP receipt also predicted fewer unmet information needs related to "follow-up care required" and "possible late effects" (adult: OR, 0.44; 95% CI, 0.20-0.96; OR, 0.29; 95% CI, 0.13-0.64; child/parent: OR, 0.46; 95% CI, 0.30-0.72; OR, 0.57; 95% CI, 0.38-0.85; respectively). In terms of distal outcomes, SCP receipt predicted a better global quality of life for adult cancer survivors (β, 0.08; 95% CI, -0.01-7.93), proxy-reported health-related quality of life (β, 0.15; 95% CI, 0.44-7.12), and satisfaction with follow-up care for childhood cancer survivors (OR, 2.93; 95% CI, 1.64-5.23). Previous studies have shown little impact of SCPs on distal end points. Results suggest that SCPs may be beneficial to cancer survivors' proximal and distal outcomes.
Sections du résumé
BACKGROUND
The impact of survivorship care plans (SCPs) on the proximal and distal outcomes of adult and childhood cancer survivors, and parent proxies, is unclear. This study aimed to determine the relationship between SCP receipt and these outcomes.
METHODS
A cross-sectional survey of adult and childhood cancer survivors (and parent proxies for survivors aged younger than 16 years) across Australia and New Zealand was conducted. Multivariate regression models were fitted to measure the impact of SCP receipt on proximal (unmet information needs and propensity to engage with, and attend, cancer-related follow-up care) and distal outcomes (quality of life and satisfaction with cancer-related follow-up care) with control for cancer history and sociodemographic factors.
RESULTS
Of 1123 respondents, 499 were adult cancer survivors and 624 were childhood cancer survivors (including 222 parent proxies). We found that SCP receipt was predictive of greater attendance at, and awareness of, cancer-related follow-up care (adult: odds ratio [OR], 2.46; 95% CI, 1.18-5.12; OR, 2.38; 95% CI, 1.07-5.29; child/parent: OR, 2.61; 95% CI, 1.63-4.17; OR, 1.63; 95% CI, 1.06-2.50; respectively). SCP receipt also predicted fewer unmet information needs related to "follow-up care required" and "possible late effects" (adult: OR, 0.44; 95% CI, 0.20-0.96; OR, 0.29; 95% CI, 0.13-0.64; child/parent: OR, 0.46; 95% CI, 0.30-0.72; OR, 0.57; 95% CI, 0.38-0.85; respectively). In terms of distal outcomes, SCP receipt predicted a better global quality of life for adult cancer survivors (β, 0.08; 95% CI, -0.01-7.93), proxy-reported health-related quality of life (β, 0.15; 95% CI, 0.44-7.12), and satisfaction with follow-up care for childhood cancer survivors (OR, 2.93; 95% CI, 1.64-5.23).
CONCLUSIONS
Previous studies have shown little impact of SCPs on distal end points. Results suggest that SCPs may be beneficial to cancer survivors' proximal and distal outcomes.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3820-3832Informations de copyright
© 2023 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.
Références
Int J Environ Res Public Health. 2021 Jun 30;18(13):
pubmed: 34209191
J Clin Oncol. 2018 Jul 10;36(20):2088-2100
pubmed: 29775389
CA Cancer J Clin. 2018 Jul;68(4):297-316
pubmed: 29846940
BMC Cancer. 2019 Aug 27;19(1):839
pubmed: 31455311
Patient Educ Couns. 2010 Mar;78(3):377-81
pubmed: 20188505
Support Care Cancer. 2007 May;15(5):515-23
pubmed: 17120068
Cancer. 2020 Feb 1;126(3):619-627
pubmed: 31626337
Support Care Cancer. 2021 Aug;29(8):4295-4302
pubmed: 33415363
Cancer. 2023 Dec 1;129(23):3820-3832
pubmed: 37566341
Int J Public Health. 2009 Sep;54 Suppl 2:160-6
pubmed: 19652910
Br J Cancer. 2014 Nov 11;111(10):1899-908
pubmed: 25314068
Psychooncology. 2007 Sep;16(9):796-804
pubmed: 17177268
Health Serv Res. 2004 Aug;39(4 Pt 1):1005-26
pubmed: 15230939
J Clin Oncol. 2013 Jul 20;31(21):2651-3
pubmed: 23796989
Lancet Oncol. 2017 Jan;18(1):e30-e38
pubmed: 28049575
J Adolesc Young Adult Oncol. 2017 Jun;6(2):327-332
pubmed: 28103126
Multivariate Behav Res. 1991 Jul 1;26(3):499-510
pubmed: 26776715
J Adolesc Young Adult Oncol. 2017 Mar;6(1):67-73
pubmed: 27529650
Acta Oncol. 2019 May;58(5):782-789
pubmed: 30698063
J Adv Pract Oncol. 2020 Jan-Feb;11(1):37-48
pubmed: 33542848
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Support Care Cancer. 2021 Jan;29(1):169-177
pubmed: 32328773
Breast Cancer. 2021 Nov;28(6):1292-1317
pubmed: 34146242
Aust J Gen Pract. 2019 Dec;48(12):833-836
pubmed: 31774985
Med J Aust. 2014 May 5;200(8):460
pubmed: 24794605
J Am Med Inform Assoc. 2021 Sep 18;28(10):2277-2286
pubmed: 34333588
JAMA. 2002 Apr 10;287(14):1832-9
pubmed: 11939869
Health Qual Life Outcomes. 2016 Sep 20;14(1):133
pubmed: 27644755
J Pediatr Hematol Oncol. 2013 Apr;35(3):193-6
pubmed: 22983417
Pediatr Clin North Am. 2020 Dec;67(6):1103-1134
pubmed: 33131537
Support Care Cancer. 2021 Jun;29(6):3049-3059
pubmed: 33040283
J Cancer Educ. 2013 Jun;28(2):290-6
pubmed: 23526552
Qual Life Res. 2018 Dec;27(12):3313-3324
pubmed: 30167937
Support Care Cancer. 2019 Oct;27(10):3785-3792
pubmed: 30721368
J Psychosoc Oncol. 2012;30(2):198-216
pubmed: 22416956
Health Serv Res. 2005 Dec;40(6 Pt 1):1918-30
pubmed: 16336556
JMIR Cancer. 2017 Sep 26;3(2):e14
pubmed: 28951383
Malays J Med Sci. 2018 Jul;25(4):122-130
pubmed: 30914854
Int J Cancer. 2022 Oct 15;151(8):1280-1290
pubmed: 35657637
Oncologist. 2020 Feb;25(2):e351-e372
pubmed: 32043786
Can Oncol Nurs J. 2021 Nov 1;31(4):451-456
pubmed: 34786462
Lancet. 2022 Apr 16;399(10334):1561-1572
pubmed: 35430023
Lancet. 2022 Apr 16;399(10334):1537-1550
pubmed: 35430021
Lancet Oncol. 2017 Mar;18(3):e153-e165
pubmed: 28271870
J Cancer Surviv. 2018 Aug;12(4):495-508
pubmed: 29572602
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
J Womens Health (Larchmt). 2013 Jun;22(6):507-17
pubmed: 23672296